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SUMMARY
Introduction Benign prostatic hyperplasia (BPH) causes disorders of voiding and sexual function. Phar-
macologic therapy reduces symptoms of voiding thus impacting sexual function.
Objective To determine sex life status in men with BPH before and after pharmacologic treatment 
adapted to achieve satisfactory sexual function.
Methods We studied 117 sexually active BPH patients, not previously treated for BPH. After clinical ex-
aminations, symptoms of voiding, sexual and ejaculatory function were measured using standardized 
IPSS, IIEF and MSHQ-EjD questionnaires. After obtaining patients’ personal opinion about the importance 
of their sex life, therapy was chosen and possible side effects explained. Three groups of 39 patients 
each were formed. The first group was treated with alpha-blocker, tamsulosin, the second with 5-alpha 
reductase inhibitor, finasteride, while the third group was administered a combination therapy. The 
complete examination procedure was repeated after 3 and 6 months of therapy.
Results The average age of patients was 61.34±3.04 years. Eighty-seven percent reported that their sex 
life was important to a certain degree. Satisfaction with their sex life was reported by 47% of patients 
before treatment and by 67% of respondents 6 months after treatment. Questionnaire scores indicated 
general improvement of sexual function in all groups, which was statistically significant compared to 
baseline only in the group on tamsulosin alpha-blocker (2.95±7.81; p=0.028). The overall satisfaction 
with sex life as a component of sexual function, improved significantly in the group on the combined 
therapy (0.78±1.81; p=0.012).
Conclusion Before BPH treatment sexual function should be assessed and therapy customized to the 
patient’s expectations. Side effects of drugs should be presented especially to patients who emphasize 
the importance of sex life. In the manifested stages of the disease overall satisfaction with sex life may 
be improved by combined therapy comprising 5-alpha reductase inhibitors and third generation alpha 
blockers. In earlier stages, BPH alpha blockers monotherapy may improve overall sexual function.
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INTRODUCTION
Benign prostatic hyperplasia (BPH) occurs in 
more than 50% of men over the age of 50. It 
leads to prostate enlargement and subvesical 
obstruction with the appearance of character-
istic lower urinary tract symptoms (LUTS), 
frequently accompanied by sexual dysfunc-
tion (SD) [1]. All of these reduce the quality of 
patient’s life [2, 3].
Longer life expectancy increases the number 
of people with a joint problem of LUTS and SD 
due to BPH [4]. Despite the decreased overall 
sexual functioning, the majority of elder men 
find their sex life an important aspect in their 
quality of life [5]. Due to the opinion that the 
symptoms of SD constitute natural conse-
quences of aging process; most older men do 
not turn for help for their sexual problems and 
medical professionals do not particularly take 
into consideration these problems [6, 7].
Leading contemporary guidelines for the 
treatment of BPH patients do not give abso-
lute indications for surgical treatment but rec-
ommend pharmacologic therapy with alpha-
blockers (AB) and 5-alpha reductase inhibitors 
(5ARI), single or in combination. For the en-
larged prostate and mild symptoms with no clin-
ical signs of obstruction the concept of Watchful 
Waiting (WW) is recommended [8, 9].
The application of AB is based on chang-
ing the tone of smooth muscular tissue of the 
bladder neck and myogenic component of 
BPH, which relax under their influence. In our 
practice, the most commonly used drug is tam-
sulosin, an AB of the third generation. It has a 
higher affinity for prostatic receptors than for 
the receptors of the smooth muscles of blood 
vessels. Its side effects include ejaculatory dys-
function (EjD), although it can improve the 
erectile function [10]. The application of 5ARI 
is based on inhibiting the enzyme by the same 
name and blocking the conversion of the inac-
tive form of testosterone to its active counterpart 
which is responsible for the anatomic growth 
and hyperplasia of prostatic glandular compo-
nents [11]. This group of drugs includes finas-
teride and dutasteride having similar clinical ef-
ficacy. Finasteride increases the risk of erectile 
dysfunction (ED), EjD and decreased sexual 
desire [12]. The combination of AB and 5ARI 
provides synergic action of both components, 
producing side effects which are a combination 
of side effects of the two types of drugs [13].     
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Pharmacologic therapy can improve the urinary flow, 
relieve BPH symptoms, beneficially affect sexual function 
and thus improve the overall quality of life [14].
OBJECTIvE
The aim of this study was to determine the degree of SD 
and LUTS in BPH, and the possibility of improving sexual 
function through pharmacologic therapy of BPH by reduc-
ing the discomfort experienced on urination.
METHODS
At the Department of Urology of the Niš Military Hospital, 
117 patients were studied in the period between February 
2011 and April 2012. Patients were aged 55-65 years, and 
were not previously treated for BPH. They were of compa-
rable socio-economic background and educational level, 
without any significant comorbidities and were sexually 
active. All of them were clinically examined. They under-
went laboratory tests including prostate specific antigen 
(PSA) and free prostate specific antigen (fPSA) markers, 
testosterone and testosterone hormones, urine culture 
testing, rectal examination, urinary tract ultrasonography 
and uroflowmetry. The basic criterion for including the 
patients in the study was the presence of moderate LUTS, 
with the prostate tissue weighing over 30 g, PSA<4 ng/mL. 
Patients with BPH complications, potential malignancy, 
residual urine >200 ml, infections, bladder calculus and 
obstructive changes in kidneys, were excluded.
The intensity of urination symptoms was measured us-
ing the International Prostate Symptom Score (IPSS-QoL, 
quality of life), the degree of SD was measured by the Inter-
national Index of Erectile Function (IIEF), whereas EjD was 
determined using the Male Sexual Health Questionnaire-
Ejaculatory Dysfunction (MSHQ-EjD). Prior to treatment, 
the patients were asked to complete a questionnaire with the 
assistance of medical professionals as necessary. The aver-
age value of the intensity of voiding symptoms did not vary 
significantly across the examined groups.
In deciding the therapy, special attention was paid to 
patients who emphasized the importance of sexual func-
tioning. They were explained the possible side effects of 
therapy (Table 1). Based on the results of analysis, ques-
tionnaires, and interviews with patients concerning their 
desired sexual function, 3 groups were formed, each con-
sisting of 39 patients. One group was administered AB 
(tamsulosin 0.4 mg/day), the second group received 5ARI 
(finasteride 5 mg/day), while the third group was given 
combination therapy (tamsulosin and finasteride). Three 
and six months after the administration of therapy follow-
up examinations were conducted which were identical to 
those done before the beginning of the study in terms of 
form and content.
AB were administered to patients with a smaller pros-
tate and moderate to severe urinary symptoms, mostly 
those emphasizing the importance of sex life. 5ARI were 
given to patients with a larger prostate (over 40 g), and 
moderate to mild urinary symptoms, mostly those who 
did not emphasize the importance of sex life. Combina-
tion therapy was given to patients with moderate to severe 
symptoms with a larger prostate (over 50 g and a higher 
PSA) and at the highest risk of disease progression, with 
different degrees of interest in sex life.
The IPSS questionnaire consists of 7 questions related 
to discomfort experienced during urination in the past 
month. Four questions are related to obstructive symp-
toms (emptying, intermittency, straining, weakness), and 
three to irritative symptoms (frequency, urgency, noctu-
ria). Each answer brings a score from 0-5 points, the maxi-
mum sum being 35, with the results being interpreted as 
follows: (0-7) mild symptoms, (8-19) moderate symptoms, 
(20-35) severe symptoms. Additional question about the 
quality of life determines the level of a patient’s subjective 
experience of symptoms with answers being graded from 
0 (best) to 6 (worst) [15].
The IIEF questionnaire consists of 15 questions for 
assessing the sexual function in the past month (with 
grades ranging from 0-5, the maximum sum being 75). 
It includes five areas: 1. erectile function (6 questions, 
the maximum sum being 30, with ratings ranging from 
very difficult to normal erections); 2. orgasmic function 
(2 questions, with the maximum sum of 10, ratings range 
from very difficult to normal orgasm); 3. sexual desire (2 
questions with the maximum sum of 10, ratings ranging 
from complete absence of sexual desire to the sexual de-
sire which is present all the time ); 4. intercourse satisfac-
tion (3 questions with the maximum sum of 15, ratings 
ranging from never satisfied to complete satisfaction); 
5. overall satisfaction with sex life (2 questions with the 
maximum sum of 10, ratings ranging from never satisfied 
to completely satisfied) [16].
As the IIEF does not provide enough data for EjD, a 
more adequate measure is the Male Sexual Health Ques-
tionnaire-Ejaculatory Dysfunction (MSHQ-EjD) Short 
Form containing four questions, and scores from 0-5. 
Three questions relate to the properties of ejaculation: 
frequency (from total absence to always present), strength 
of ejaculation (from total absence to normal strength) and 
the volume of ejaculation (from total absence to normal 
amount). The fourth question regards the patients’ con-
cern about their ejaculatory condition (ranging from the 
condition without any problems to deep concerns) [17].
Table 1. Distribution of therapy according to the importance of sex 
life (number of patients)
Sex life
Groups of patients
AB 5ARI CTh Total
Very important 11 (28%) 3 (8%) 8 (20%) 22 (19%)
Important 19 (49%) 9 (23%) 17 (44%) 45 (38%)
Occasionally 
important 7 (18%) 19 (49%) 9 (23%) 35 (30%)
Not important 2 (5%) 8 (20%) 5 (13%) 15 (13%)
Total 39 (100%) 39 (100%) 39 (100%) 117 (100%)
AB – alpha-blocker; 5ARI – 5-alpha reductase inhibitors; CTh – combination 
therapy  
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Statistical analysis was performed using a 2.2.1 version 
of the R computer software (R Foundation for Statistical 
Computing, Vienna, Austria). The implied statistical sig-
nificance was p<0.05. The values of all scores are shown 
as a mean value ± standard deviation. Two patients from 
the AB and the combination therapy group respectively 
failed to undergo check-up number 3 for objective reasons 
which were taken into account in the statistical analysis.
Testing the differences between the scores at the begin-
ning of the research, and those obtained 3 and 6 months 
after the use of therapy was performed through the analy-
sis of variance for repeated measuring (RM ANOVA). The 
comparison of changes occurring in score values obtained 
during the research of three therapy groups as well as the 
age of patients of all four groups was made using the one-
way ANOVA variance analysis and the Tukey post-hoc 
test.
RESULTS
The average age of all respondents was 61.34±3.04. The 
average age by groups was as follows: the group on AB 
60.69±3.22 years, the group on 5ARI 61.56±3.30, and the 
group receiving combined therapy 61.76±2.51. There were 
no statistically significant age differences between com-
pared groups.
Sex life was reported to be very important by 19% of 
patients; 38% found it important; it was rated as sometimes 
important by 30% and not important by 13%, who never-
theless engaged in sexual intercourse. All three groups ex-
perienced significant improvement in urinary symptoms 
(IPSS) and the quality of life (Tables 2 and 3).
According to the results of the questionnaire, the overall 
sexual function (IIEF) improved most in patients on com-
bination therapy (3.24±11.3), followed by the AB group 
(2.95±7.81), while least improvement was experienced by 
patients receiving only 5ARI (0.64±10.23). Statistically sig-
nificant improvement of overall IIEF scores within groups 
compared to those at baseline occurred only in the group 
on AB (p=0.028).
The results of the IIEF questionnaire regarding particu-
lar elements of sexual function were as follows:
Erectile function improved most in patients using 
only AB (2.46±3.73; p<0.001), followed by those on com-
bination therapy (2.19±5.14; p=0.014), while least im-
provement was experienced by respondents using 5ARI 
(1.64±4.96; p=0.046).
The orgasmic function deteriorated in all groups. 
This deterioration was the worst in the group on AB 
(-1.03±1.94; p=0.003), followed by the group using com-
bination therapy (-0.76±2.07; p=0.033), statistically sig-
nificant for both groups, while the respondents receiving 
5ARI experienced least deterioration.
During research, sexual desire improved in patients 
on AB (0.78±1.00), while those receiving only 5ARI ex-
perienced deterioration (-0.54±1.68). A statistically sig-
nificant difference was confirmed between these changes 
(p=0.001). In patients using the combination therapy there 
was a slight improvement which was not significantly dif-
ferent from the changes developed in two other therapy 
groups. The only group experiencing a statically signifi-
cant improvement compared to that at baseline was the 
group on AB (p<0.001).
Intercourse satisfaction in patients on 5ARI declined 
(-0.13±2.26), while those receiving AB experienced im-
provement of 0.81±1.98; the improvement in patients on 
the combination therapy was 0.76±2.50. Again, the AB 
group was the only one experiencing a significant improve-
ment compared to the condition at baseline (p=0.018).
Overall satisfaction with sex life improved in all groups 
but significant improvement compared to that at baseline 
was only found in the group on the combination therapy 
(p=0.012).
The results of MSHQ-EjD questionnaires are as follows:
Ejaculatory dysfunction deteriorated in all groups. In 
patients on AB (-4.38±2.55) and those receiving the com-
bination therapy (-3.89±2.84), although there were no 
significant differences between these changes, they were 
statistically significantly higher (p<0.001) than in respond-
ents on 5ARI (-1.49±2.52).
Bother score values increased most in the group on AB 
(1.86±1.62). This change is significantly higher in com-
parison with the group using 5ARI (0.56±1.43; p=0.001), 
but not in comparison to the group on the combination 
therapy (1.41±1.61). The increase of these score values was 
higher in respondents on the combination therapy than in 
those using 5ARI, but without any statistical significance.
On the other hand, by giving their unique personal 
opinion before therapy when asked whether or not they 
were satisfied with their sexual functioning, patients re-
plied as follows: satisfied 47% (55 respondents); indifferent 
22% (26); dissatisfied 26% (31).
After 6 months of therapy, 67% (78 patients) were sat-
isfied. Twenty-one percent (25) found their condition 
unchanged without any complaints, generally those who 
rated their sex life as unimportant or occasionally impor-
tant. Twelve percent (14) were concerned, mainly due to 
decreased sexual desire or EjD.
DISCUSSION
The application of pharmacologic therapy led to a statis-
tically significant improvement in symptoms of overall 
sexual function (IIEF) only in the AB group compared 
with the condition at baseline. This can be accounted for 
with the quickest response to therapy, as the improvement 
of symptoms occurs only days after drug administration. 
Relaxation of smooth muscles of the bladder and prostate 
tissue result in a better penile blood supply which in turn 
improves erectile function [18]. Despite the decline of the 
orgasmic function and the decrease or absence of ejacula-
tion, patients experienced a significant improvement in 
the intercourse satisfaction and sexual desire. Decreased 
ejaculation is not perceived so negatively as erectile dys-
function (ED) which all results in the improvement of the 
quality of life.     
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The latest study by Orabi et al. [19] points out that there 
are different opinions on the ability of AB therapy on the 
result in the improvement of sexual function as it is diffi-
cult to determine whether this kind of treatment improves 
LUTS and consequently ED, or whether the treatment ef-
fects each process independently. Kumar et al. [20] con-
firm the improvement in sexual function as a result of 
AB use. Kobayashi et al. [21] point out that the concerns 
over side effects of AB therapy are little as the orgasm is 
preserved despite decreased ejaculation.
The effects of 5ARI, despite causing significant im-
provement of urinary symptoms which led to a better 
quality of life, did not cause any significant changes in 
overall sexual function (IIEF). According to our findings, 
unlike the findings of some other studies, erectile func-
tion was the only one to improve. Still, due to the declined 
Table 2. Score values during examination
Group and score
Testing (mean±SD) Comparison between testings (p)
Baseline After 3 
months
After 6 
months I vs. II II vs. III I vs. III
Alpha blocker
IPSS score-total (max 35) 13.64±3.35 9.21±2.66 7.51±2.66 <0.001* 0.001* <0.001*
QoL (0-6) 3.74±.75 1.79±0.89 1.32±0,85 <0.001* 0.006* <0.001*
IIEF score-total (max 75) 51.46±11.25 53.77±10.43 54.73±11.14 0.025* 0.667 0.028*
Erectile function (max 30) 20.82±5.38 22.64±5.14 23.41±5.41 0.001* 0.294 <0.001*
Orgasmic function (max 10) 8.36±1.88 7.67±1.84 7.35±1.72 0.043* 0.066 0.003*
Sexual desire (max 10) 6.69±1.49 7.31±1.47 7.46±1.41 0.005* 0.554 <0.001*
Intercourse satisfaction (max 15) 9.00±2.53 9.62±2.52 9.86±2.31 0.042* 0.581 0.018*
Overall satisfaction with sex life (max 10) 6.36±1.81 6.54±1.47 6.70±1.71 0.747 0.603 0.436
EjD-total (max 15) 10.49±2.43 7.46±2.67 6.22±2.31 <0.001* 0.001* <0.001*
Bother (0-5) 1.51±1.14 2.74±1.09 3.30±0.97 <0.001* 0.013* <0.001*
5ARI
IPSS score (max 35) 16.69±2.91 10.97±2.45 7.69±2.62 <0.001* <0.001* <0.001*
QoL (0-6) 4.10±0.64 1.97±0.84 1.26±0.79 <0.001* <0.001* <0.001*
IIEF score-total (max 75) 47.85±11.95 49.49±10.04 48.49±10.68 0.217 0.443 0.698
Erectile function (max 30) 18.82±5.87 20.08±5.21 20.46±5.24 0.051 0.528 0.046*
Orgasmic function (max 10) 7.92±2.02 8.00±1.45 7.38±2.07 0.760 0.010 0.053
Sexual desire (max 10) 6.56±1.52 6.41±1.50 6.03±1.46 0.504 0.141 0.053
Intercourse satisfaction (max 15) 8.64±2.36 8.74±1.97 8.51±2.00 0.775 0.373 0.725
Overall satisfaction with sex life (max 10) 5.90±1.89 6.23±1.66 6.10±1.31 0.217 0.585 0.440
EjD-total (max 15) 9.26±2.68 8.49±2.13 7.77±2.50 0.004* 0.035* 0.001*
Bother (0-5) 1.97±1.25 2.26±1.02 2.54±0.97 0.070 0.155 0.018*
Combination 
therapy
IPSS score (max 35) 19.82±3.09 12.05±2.65 8.89±2.60 <0.001* <0.001* <0.001*
QoL (0-6) 4.33±0.70 2.10±1.02 1.41±0.86 <0.001* <0.001* <0.001*
IIEF score-total (max 75) 41.46±12.90 42.41±11.94 44.35±12.76 0.347 0.192 0.089
Erectile function (max 30) 16.74±6.30 17.51±5.64 18.70±5.99 0.167 0.063 0.014*
Orgasmic function (max 10) 6.79±2.25 6.10±2.09 5.97±2.32 0.048* 0.650 0.033*
Sexual desire (max 10) 5.92±1.68 6.10±1.55 6.19±1.60 0.382 0.918 0.368
Intercourse satisfaction (max 15) 7.10±2.36 7.38±2.36 7.81±2.40 0.268 0.306 0.074
Overall satisfaction with sex life (max 10) 4.87±1.72 5.21±1.79 5.65±1.80 0.218 0.016* 0.012*
EjD-total (max 15) 8.56±3.08 5.77±2.75 4.59±2.50 <0.001* <0.001* <0.001*
Bother (0-5) 1.85±1.25 2.92±0.93 3.32±1.08 <0.001* 0.023* <0.001*
* p<0.05
SD – standard deviation; IPSS – International Prostate Symptom Score; IIEF – International Index of Erectile Function; QoL – Quality of Life; EjD – ejaculatory 
dysfunction; 5ARI – 5-alpha reductase inhibitors
Table 3. Comparison of score changes in the period between the first and third testing
Score
Groups (Mean±SD) Comparison between groups (p)
AB 5ARI CTh I vs. II I vs. III II vs. III
IPSS score-total (max 35) -5.84±3.08 -9.00±2.84 -10.95±3.19 <0.001* <0.001* 0.017*
QoL (0-6) -2.32±1.00 -2.85±1.01 -2.95±0.97 0.062 0.023* 0.900
IIEF score-total (max 75) 2.95±7.81 0.64±10.23 3.24±11.30 0.569 0.997 0.488
Erectile function (max 30) 2.46±3.73 1.64±4.96 2.19±5.14 0.725 0.966 0.865
Orgasmic function (max 10) -1.03±1.94 -0.54±1.68 -0.76±2.07 0.504 0.814 0.871
Sexual desire (max 10) 0.78±1.00 -0.54±1.68 0.27±1.81 0.001* 0.328 0.062
Intercourse satisfaction (max 15) 0.81±1.98 -0.13±2.26 0.76±2.50 0.170 0.994 0.207
Overall satisfaction with sex life (max 10) 0.22±1.67 0.21±1.64 0.78±1.81 0.999 0.329 0.306
EjD-total (max 15) -4.38±2.55 -1.49±2.52 -3.89±2.84 <0.001* 0.708 <0.001*
Bother (0-5) 1.86±1.62 0.56±1.43 1.41±1.61 0.001* 0.430 0.052
* p<0.05  
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sexual desire, and consequentially a decreased frequency 
of sexual intercourse and orgasmic function, no changes 
occurred either in the intercourse satisfaction or in the 
overall satisfaction with sex life.
Hellstrom et al. [22] emphasize that the exact mecha-
nism of 5ARI action leading to sexual dysfunction with 
the frequency of sexual side-effects declining with the 
prolonged use of therapy is not known. The PLESS study 
also shows that men treated with finasteride experienced 
sexual side effects more frequently during the first year 
of therapy [23]. Despite potential undesirable effects on 
sexual function, the latest study by Parsons et al. [24] rec-
ommends the use of finasteride in the prevention of clini-
cal BPH and prostate cancer in older men.
Combination therapy groups compared to monothera-
py groups showed a significant improvement of overall 
sex life (IIEF) and significant improvement of urinary 
symptoms. It provides the synergic effect of both compo-
nents with the side effects being the combination of side 
effects of each type of drug. Compared to the condition at 
baseline, erectile function and overall satisfaction with sex 
life significantly improved. Despite the significantly lower 
orgasmic function, the dominantly positive effect of other 
elements of sexual function resulted in the significant im-
provement in the quality of life.
The latest Combat study on therapy with tamsulosin 
and dutasteride shows that the overall side effects occur 
significantly more frequently during combination therapy 
than monotherapy. No significant difference in the fre-
quency of sexual side effects occurrence between the two 
available 5ARI (finasteride and dutasteride) were found. 
Comparing the effects of monotherapy with AB and 5ARI, 
the combination therapy leads to a greater improvement in 
LUTS and a better prevention of disease progression [25].
Most of LUTS in BPH is subjective, whereby the degree 
of the severity of symptoms is significant in choosing the 
method of treatment [26]. A certain number of patients 
are well-adapted to a greater discomfort, while others with 
minimal symptoms are highly upset and actively seek 
treatment. During examination, it is important to get in-
formation not only about the symptoms of voiding but also 
about sexual symptoms [27]. When deciding on the treat-
ment, providing a careful explanation of possible side ef-
fects of drugs on sexual function, with a moderate positive 
suggestion, helps patients accept these side effects more 
readily and do not perceive them as necessarily negative. 
By stressing the expected beneficial outcomes of therapy, 
the placebo effect is somewhat emphasized, and indicates 
the significance which the power of autosuggestion has 
on patients’ expectations in believing that their condition 
will improve. Patients should be included in making a de-
cision about the treatment process, keeping in mind that 
the risk is more significant if a younger man is concerned 
[28]. A nocebo effect, which aggravates results, should be 
prevented in patients who fail to obtain enough informa-
tion themselves. Sometimes a significant improvement in 
voiding is identified with a better sex life, while the results 
of questionnaires show no change or even deterioration.
A general assessment on whether or not a person is 
satisfied with their sex life after treatment, can be signifi-
cantly more favorable than the results of the questionnaire, 
i.e. it does not reflect the real condition. The question-
naires with specific questions provide detailed analysis of 
all aspects of sexual life and give a more accurate result of 
current condition. At the same time a personal opinion 
on what makes one person happy but not the other one 
should be taken into account. Even those to whom their 
sex life was sometimes important or not that important, 
were satisfied with the administered therapy. So long as 
they function well an occasional sexual intercourse makes 
them very happy. Through the selection of patients based 
on the criteria of the importance of their sex life and the 
acknowledgement of clinical findings and side effects we 
achieved an overall improvement in sex life for most pa-
tients, with the improvement of voiding symptoms and 
increase of the quality of life. Standardized questionnaires 
on sexual function can be used to measure the intensity of 
symptoms, select patients for appropriate pharmacologic 
treatment and subsequently assess the results of treatment 
[29].
Sex life can also significantly be improved by using 
drugs from the phosphodiesterase-5 (PDE5) inhibitors 
group, which were not used in this study, as these drugs 
are currently less financially affordable for most patients 
in our country.
CONCLUSION
Each examination concerning BPH should determine the 
level of the patient’s urinary symptoms and sexual func-
tion status using standardized questionnaires. Depending 
on the test results and interest in sexual function, therapy 
should be chosen and possible side effects explained. 
Overall satisfaction with sex life can be achieved in mani-
fested stage of illness with combined therapy comprising of 
5-alpha reductase inhibitors and a third generation alpha 
blocker. In earlier stages, alpha blockers monotherapy may 
improve overall sexual function. By improving voiding 
symptoms, preventing disease progression, and improv-
ing sexual function, the effects of pharmacologic treatment 
of BPH are more complete.
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КРАТАК САДРЖАЈ
Увод Бе  ниг  на хи  пер  пла  зи  ја про  ста  те (БХП) про  у  зро  ку  је по-
ре  ме  ћа  је и мо  кре  ња и сек  су  ал  не функ  ци  је. Ме  ди  ка  мент  на 
те  ра  пи  ја сма  њу  је те  го  бе при мо  кре  њу, при че  му ути  че на 
сек  су  ал  ну функ  ци  ју.
Циљ ра  да Циљ ис  тра  жи  ва  ња је био да се утвр  ди ста  ње сек-
су  ал  ног жи  во  та му  шка  ра  ца са БХП пре и по  сле ко  ри  шће  ња 
ме  ди  ка  мент  не те  ра  пи  је, при  ла  го  ђе  не по  сти  за  њу за  до  во  ља-
ва  ју  ће сек  су  ал  не функ  ци  је.
Ме  то  де ра  да Ис  пи  та  но је 117 сек  су  ал  но ак  тив  них му  шка  ра-
ца са БХП ко  ји ра  ни  је ни  су ле  че  ни због БХП. На  кон кли  нич-
ког ис  пи  ти  ва  ња, симп  то  ми мо  кре  ња, сек  су  ал  не и еја  ку  ла-
ци  о  не функ  ци  је ме  ре  ни су по  пу  ња  ва  њем стан  дар  ди  зо  ва  них 
упит  ни  ка IPSS, IIEF и MSHQ-EjD. Уз лич  ну оце  ну бо  ле  сни  ка о 
ва  жно  сти свог сек  су  ал  ног жи  во  та, те  ра  пи  ја је од  ре  ђи  ва  на 
уз об  ја  шње  ње мо  гу  ћих спо  ред  них ефе  ка  та. Обра  зо  ва  не су 
три гру  пе са по 39 ис  пи  та  ни  ка. Јед  на гру  па је у те  ра  пи  ји 
при  ме  њи  ва  ла ал  фа-бло  ка  тор там  су  ло  зин, дру  га гру  па ин  хи-
би  тор 5-ал  фа ре  дук  та  зе фи  на  сте  рид, а тре  ћа гру  па бо  ле  сни-
ка ком  би  но  ва  ну те  ра  пи  ју. Ком  пле  тан по  сту  пак ис  пи  ти  ва  ња 
по  на  вљан је на  кон три ме  се  ца и шест ме  се  ци ле  че  ња.
Ре  зул  та  ти Про  сеч  на ста  рост ис  пи  та  ни  ка би  ла је 61,34±3,04 
го  ди  не. О то  ме да им је сек  су  ал  ни жи  вот у не  ком сте  пе  ну 
ва  жан из  ја  сни  ло се 87% ис  пи  та  ни  ка. Сво  јом сек  су  ал  ном 
функ  ци  јом пре те  ра  пи  је би  ло је за  до  вољ  но 47% ис  пи  та  ни-
ка, а на  кон шест ме  се  ци 67%. Пре  ма ре  зул  та  ти  ма упит  ни  ка, 
сек  су  ал  на функ  ци  ја у це  ли  ни је по  бољ  ша  на у свим гру  па-
ма, али ста  ти  стич  ки зна  чај  но у од  но  су на по  че  так ле  че  ња у 
гру  пи бо  ле  сни  ка ко  ји су при  ма  ли ал  фа-бло  ка  тор там  су  ло-
зин (2,95±7,81; p=0,028). Укуп  но за  до  вољ  ство сек  су  ал  ним 
жи  во  том зна  чај  но је по  бољ  шано у гру  пи бо  ле  сни  ка ко  ји су 
при  ма  ли ком  би  но  ва  ну те  ра  пи  ју (0,78±1,81; p=0,012).
За  кљу  чак Пре по  чет  ка ле  че  ња БХП тре  ба  ло би оце  ни  ти сек-
су  ал  ну функ  ци  ју сва  ког бо  ле  сни  ка. Те  ра  пи  ју би тре  ба  ло при-
ла  го  ди  ти оче  ки  ва  њи  ма бо  ле  сни  ка, а ва  жно је и пре  до  чи  ти 
им спо  ред  не ефек  те ле  ко  ва, по  го  то  ву они  ма ко  ји на  гла  ша-
ва  ју ва  жност сек  су  ал  ног жи  во  та. Код из  ра  же  ног ста  ди  ју  ма 
бо  ле  сти укуп  но за  до  вољ  ство сек  су  ал  ним жи  во  том се мо  же 
по  бољ  ша  ти ком  би  но  ва  ном те  ра  пи  јом ин  хи  би  то  ром 5-ал  фа 
ре  дук  та  зе и ал  фа-бло  ка  то  ром тре  ће ге  не  ра  ци  је. Код бла-
жег ста  ди  ју  ма БХП мо  но  те  ра  пи  ја ал  фа-бло  ка  то  ри  ма мо  же 
по  бољ  ша  ти укуп  ну сек  су  ал  ну функ  ци  ју.
Кључ  не ре  чи: про  ста  та; сек  су  ал  ни жи  вот; там  су  ло  зин; 
фи  на  сте  рид
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